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Abstract We reported that PAX6 suppresses glioblas-
toma cell growth in vivo and anchorage-independent
growth without signiﬁcant alteration of cell proliferation
in vitro, suggesting that PAX6 may alter the tumor micro-
environment. Because we found that PAX6 downregulates
expression of the gene encoding vascular endothelial
growth factor A (VEGFA) in glioma cells, we used a sub-
cutaneous xenograft model to verify PAX6 suppression of
VEGFA-induced angiogenesis based on CD31-immuno-
staining of endothelial cells. The results showed a signiﬁ-
cant reduction of VEGFA at the transcription level in
PAX6-transfected cells in xenografts and PAX6 has a
suppressive effect on the microvascular ampliﬁcation typ-
ically seen in glioblastoma. We showed that PAX6 sup-
pression of VEGFA expression requires its DNA binding-
domain. The C-terminal truncation mutant of PAX6, how-
ever, did not show the dominant negative function in reg-
ulating VEGFA expression that it showed previously in
regulating MMP2 expression. In the glioma cell line
U251HF, we further determined that blocking the PI3K/Akt
signaling pathway with either adenoviral-mediated PTEN
expression or LY294002 enhanced PAX6-mediated sup-
pression of VEGFA in an additive manner; thus, PAX6-
mediated suppression of VEGFA is not via the canonical
pathway through HIF1A. These two VEGFA-regulatory
pathways can also be similarly modulated in another
malignant glioma cell line, U87, but not inLN229 where the
basal VEGFA level is low and PTEN is wild-type. PAX6
suppression of VEGFA appears to be blocked in LN229. In
conclusion, our data showed that PAX6 can initiate in gli-
oma cells a new signaling pathway independent of PI3K/
Akt-HIF1A signaling to suppress VEGFA expression.
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Introduction
PAX6 is an early central-nervous-system (CNS) regulatory
gene which has pleotropic effects during development of
both the CNS and eye [1–3], and it contributes to both
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player regulating proliferation and differentiation through
the control of expression of different downstream mole-
cules in a highly context-dependent manner [4]. We have
identiﬁed PAX6 as a glioma tumor suppressor gene, based
on data showing PAX6 underexpression in higher grade
gliomas as opposed to lower grade, in high tumorigenic
glioma cell lines in comparison with low- and non-
tumorigenic ones, suppression of glioma-cell anchorage-
independent growth, invasion, and tumorigenicity, and
sensitization of glioma cells to detachment-induced stress
[5–8]. Since glioma cells with stable expression of ectopic
PAX6 cDNA showed dramatically suppressed growth
in vivo, but no signiﬁcant alteration of cell proliferation
in vitro, it appears that PAX6 suppression of glioma
tumorigenicity is mediated through changes in the tumor
microenvironment, e.g. suppression of tumor angiogenesis.
Microvascular ampliﬁcation is a histopathology hall-
mark in diagnosis of glioblastoma multiforme (GBM)—the
highest grade and the most common type of glioma [9].
Vascular endothelial growth factor A (VEGFA) is the
major angiogenic factor that is overexpressed in GBM [5].
An antiangiogenic agent effective in glioma, Bevacizumab
(monoclonal antibody), blocks secreted VEGFA and sig-
niﬁcantly prolongs survival in patients with malignant
glioma. Several small-molecule tyrosine-kinase inhibitors
of the VEGFRA receptor show promise as well. Unfortu-
nately despite promising overall results, more then 30% of
patients initially fail to respond to anti-angiogenic treat-
ment, and ultimately all patients will relapse and shortly
thereafter die of their disease [10]. Understanding path-
ways abnormally suppressed/activated in glioma cells to
affect VEGFA gene expression and VEGFA-induced
angiogenesis will improve our understanding of resistance
to anti-angiogenic therapies for malignant gliomas.
Enhanced expression of the VEGFA gene by glioma cells
was found to occur through the stabilization of hypoxia-
inducible factor 1 alpha (HIF1A) under hypoxic conditions
[11, 12], through the expression of the gene encoding tissue
factor (TF)[ 13–16], or through direct suppression of pro-
moter activity mediated by the von Hippel-Lindau tumor
suppressor gene (VHL)[ 17]. The action of phosphatase and
tensin homolog (PTEN), a tumor suppressor, in suppressing
VEGFA expression has been shown to occur via downreg-
ulation of HIF1A in a normoxic environment, which is
mediated by blocking of the PI3K/Akt signaling pathway—
an oncogene pathway active in malignant glioma known to
be inactivated by PTEN [18].
By examining gene expressions in four GBMs and their
adjacent normal tissues, we found that PAX6 levels were
low while VEGFA levels were high in all four of the GBMs
relative to adjacent normal tissues from the same patients
[19], suggesting that PAX6 may suppress VEGFA gene
expression in glioma cells. Here we report our study of
PAX6 in glioma cell expression of VEGFA and glioma
angiogenesis, and interestingly, co-regulation by PAX6 and
PTEN of VEGFA expression in glioma cells.
Materials and methods
Cell lines, stable transfectants, and adenoviral vectors
Thefollowingcelllinesweredescribedinourpreviousstudy
[7]: GBM cell lines U251HF, U87 and LN229, and stable
PAX6 transfectants of U251HF established through trans-
fection of a plasmid vector (pRC-CMV) expressing 1: wild-
type PAX6, 2: C-terminal truncated PAX6 (PAX6-344), 3:
mutant form of PAX6 with two mutations (R26G and I87R)
in the DNA-binding domain (PD-dmt). The adenoviral
vectors for PAX6 (Ad-PAX6) and GFP (Ad-GFP) were
describedinourpreviousstudy[6].Theadenoviralvectorfor
PTEN(Ad-PTEN)andGFP(Ad-GFP)are fromDr. T.J.Liu
(M.D. Anderson Cancer Center), which is the same adeno-
virus type-5 vector as that of Ad-PAX6. Cells were cultured
in a DMEM/F12 medium supplemented with or without 5%
calfserumin37Cundernormoxicconditionswith5%CO2.
A hypoxic condition in experiment was established using a
sealed chamber ﬁlled with 95% N2 and 5% CO2.
Subcutaneous (s.c.) implantation
Cells of either U251HF or stable transfected U251HF
expressing ectopic PAX6 (PAX6_2.2), were suspended in
DMEM/F12 medium, and 5 9 10
6 cell in 50 ll were
subcutaneously (s.c.) injected into 4 to 6-week-old female
NCrNu-M mice (Taconic, Hudson, NY). Three mice per
group were treated, and s.c. injections were anterior to their
right and left thighs. Mice were terminated at 25 days after
the implantation, and the tumors were dissected, weighted
and subjected to RNA extraction as described previously
[20]. The s.c. experiment was repeated three times.
Immunohistochemistry analyses of s.c. xenografts
Mice with s.c. xenografts were euthanized, and xenografts
were removed and embedded in cryopreservation medium
on dry ice. The cryosections were cut 10 lm thick and
mounted on cleaned glass slides. After 1 h of 37C drying,
the sections were stored at -80C. Before immunohisto-
chemistry, sections were removed from -80C, incubated
5–10 min in the oven at 37C, and ﬁxed in 4% PFA for 20–
30 min at room temperature. Endothelial cells were stained
immunohistochemically with primary rat anti-mouse PE-
CAM-1 [CD31] antibody (1:300) from Millipore Corp
(Temecula, CA), using hematoxylin to counterstain the
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and DAB detection system from BioGenex (San Ramon,
CA).Imagesweretakenontheedgeandcentralpartoftumor
sections,andbloodvesseldensity(BVD)wascalculated.We
alsoperformeddouble-stainingofxenograftsectionswithrat
anti-CD31 antibody (1:100) and rabbit anti-PAX6 antibody
(1:1,000, kindly provided by Dr. Gary Philips), double-
staining with mouse anti-VEGF (1:100) and rabbit
anti-PAX6 antibodies, and immunoﬂuorescence detection
with ﬂuorescein anti-mouse IgG (H ? L) and rhodamine
anti-rabbit IgG (H ? L) (Minipore Corp), using DAPI to
counterstain the nucleus. Image analysis procedure and
deﬁnitions of microvascular parameters were followed in
reference [21].
Modulated imaging (MI)
The MI system has been developed at the Beckman laser
institute and medical clinic, and the details of the system
have been described previously [22]. We applied the MI
technique to determine angiogenesis in vivo non-inva-
sively. Brieﬂy, the MI instrument uses patterned illumi-
nation and camera-based detection to obtain quantitative
subsurface images of biological tissues over a wide ﬁeld of
view, with information on the optical properties of the
tissue being imaged. Imaging at multiple wavelengths
(between 650 and 980 nm) provides quantitative measures
of the in vivo concentrations of oxy- (OHb), deoxy- (RHb)
and total hemoglobin (THb) from subcutaneous xenografts.
Oxygen saturation (StO2) is a ratio of OHb to THb.
Real-time absolute quantitative reverse transcription
(AqRT-) PCR
The cDNA was reverse transcribed from 0.2 to 2 lgo f
total RNA from the glioma cell lines, transfectants, and s.c.
xenografts using 5 units of Superscript II reverse trans-
criptase (Invitrogen, Carlsbad, CA). The cDNA was diluted
30 times with 10 mM Tris–HCl (pH = 7.5) and quantiﬁed
for VEGFA, VHL, and internal reference genes (GAPDH
and ENO1) by real-time PCR with human-gene-speciﬁc
primers (Ziren Research, Irvine, CA). Standard curves
were used to determine quantities of the transcripts in
cDNA samples. Absolute quantiﬁcation of VEGFA and
VHL expressions relative to reference genes (GAPDH or
ENO1) was achieved by using the single standard for both
target and reference genes provided by Ziren Research
LLC (Irvine, CA). The primer set for VEGFA was designed
to amplify all seven transcription variants of VEGFA
reported in GeneBank. The primer set for GAPDH and
ENO1 were designed to avoid ampliﬁcation of pseudo-
genes that have high sequence similarities to the genes’
cDNA sequences. The primer set for VHL speciﬁcally
ampliﬁes VHL transcription variant 1 (NM_000551).
Primer sequence information is available upon request to
Ziren Research LLC (www.zirenresearch.com).
Western hybridization and VEGFA enzyme
immunometric assay
Whole cell lysate extraction, western blotting, and PAX6
antibody were described previously [17]. Antibodies of Akt,
Phopho-Akt (Ser473), and Phospho-GSK3b (Ser9) were
from Cell Signaling Technology (Beverly, MA), while
PTEN (A2B1) was from Santa Cruzis (Santa Cruz, Califor-
nia),andActinwasfromEMD Bioscience(SanDiego, CA).
AhumanVEGFAenzymeimmunometricassay(ELISA)kit
(Assay Designs, Ann Arbor, MI) was used for quantiﬁcation
of the secretory VEGF165 in the conditioned media
according to the manufacturer’s instructions.
VEGFA promoter luciferase assay
The VEGFA promoter-luciferase constructs were a gener-
ous gift from V. P. Sukhatme (Beth Israel Deaconess
Medical Center, Harvard Medical School) [17]. Transient
transfection assay were performed using cells (250,000
cells per 35 mm dish plated 1 day before transfection) of
U251HF and three clones of U251HF expressing ectopic
PAX6 with 0.1 lg pRL-CMV expressing Renilla luciferase
as an internal control together with 1 lg VEGFA promoter
constructs. Cell were cultured in serum-free medium for
48 h before harvesting cells for detection of luciferase
activity using a Dual-Luciferase Reporter Assay System
(Promega, Madison, WI) and a TD-20/20 Luminometer
(Turner Designs, Sunnyvale, CA).
Infection of Ad-PAX6 and Ad-PTEN in GBM cells
Cells (U251HF, U87 and LN229) in triplicate were plated
in 35-mm wells at a density of 4 9 10
5 cells per well and
cultured overnight in DMEM/F12 medium supplemented
with 5% calf serum. Cells were then infected in serum-free
medium with adenovirus, 50 viral particles per cell for
single infection and 25 viral particles per cell for double
infection of Ad-PAX6 and Ad-PTEN together or 1 day
apart. Cells were grown in normoxic or hypoxic (95% N2,
5% CO2) for 24 or 48 h after infection, and then subjected
to RNA extraction and cDNA synthesis for real-time
AqRT-PCR. The medium was taken for VEGFA ELISA.
Statistical analysis
Data from real-time AqRT-PCR, ELISA, and luciferase
assayswerelog-transformedtostabilizevarianceandreduce
right-skewing. In some experiments, data were further
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independent experiment replication. Depending on the
designandnumberofgroups,statisticalanalysisconsistedof
two-sample t-test, one-way ANOVA or randomized-block
ANOVA. Multiple-comparison adjustments in ANOVA
post-hoc analysis includedDunnett’s procedure forpairwise
comparisons of treatment groups to the control group, and
Bonferroni’s procedure for other pre-planned comparisons
of interest. All analyses were conducted using SAS version
9.1.3 (The SAS Institute, Cary, NC).
Results
PAX6 suppress angiogenesis in glioma subcutaneous
xenografts
We have tested multiple clones of the stable PAX6-trans-
fected glioblastoma cell line U251HF in our previous study,
and concluded that it was PAX6, not the clonal artifact, that
suppressed U251HF cells’ anchorage-independent growth,
tumorigenicity and invasiveness, and that the vector-trans-
fected clones showed no signiﬁcant difference in these
functional aspects to parental cells [6, 7]. Here we investi-
gated PAX6 regulation of glioma-cell-induced angiogenesis
in subcutaneous (s.c.) xenografts derived from one of the
transfectants (PAX6_2.2), in comparison with that from
the parental cells. Consistent with our previous ﬁnding, the
PAX6_2.2 cells form signiﬁcantly smaller tumors com-
pared to the parent cell U251HF after s.c. implantation in
nude mice (Fig. 1a). Immunohistochemical (IHC) analysis
of endothelial cell marker CD31, as shown in Fig. 1b,
reveals that there is a signiﬁcant reduction in the number
and size of blood vessels in xenografts of PAX6_2.2 com-
pared to that of U251HF. IHC analysis revealed severe
central necrosis in U251HF s.c. xenografts 25 days after
implantation, and signiﬁcantly fewer blood vessels in the
central necrotic area compared to the periphery. We thus
Fig. 1 PAX6 overexpression in glioma cell line U251HF suppresses
cell tumorigenicity, tumor angiogenesis and VEGFA expression.
a Comparison of the weights of U251HF (n = 8) and its PAX6 stable
transfectant PAX6-2.2 xenografts (n = 24) 24 days after subcutane-
ously implantation in nude mice. Fold change is 3.85; P\0.0001 by
two-sample t-test. b Immunoﬂuroscent analysis of the xenografts
from a for expression of PAX6 and CD31, with counterstaining of
nuclei by DAPI. See [21] for image analysis procedure and deﬁnitions
of microvascular parameters. c Comparison of blood vessel density
(BVD) normalized to peripheral region of U251HF tumor.
d Comparison of total hemoglobin (THb) concentration and tissue
oxygen saturation (StO2) in the two groups of s.c. xenografts (four
tumors each group, two mice per group) by modulated imaging, all
were subjected to CD31-IHC for BVD data above. Two-sample t-test
P values were 0.043 for THb, and 0.70 for StO2, after Tukey-adjusted
for comparisons among groups. e VEGFA expression in the s.c.
xenografts from a by real-time AqRT-PCR. Fold change is 2.52 as
shown; P = 0.025 by two-sample t-test
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periphery regions of U251HF xenograft to that from an
overall region of xenografts from PAX6-2.2 that showed a
more even distribution of blood vessels. As shown in
Fig. 1c, there is a signiﬁcantly lower BVD in tumor from
PAX6_2.2 cells (Fig. 1c).
To conﬁrm histological data, we analyzed a group of
mice carrying the tumor with modulated imaging (MI) to
monitor the blood uptake and consumption in tumor
in vivo [22]. MI data revealed that PAX6-2.2 xenografts
have signiﬁcantly lower levels of both oxy-hemoglobin
(OHb) and deoxy-hemoglobin (RHb) compared to U251HF
xenograft. Consequently, as shown in Fig. 1d, PAX6-2.2
xenografts have a signiﬁcantly lower level of total hemo-
globin (THb) (sum of OHb and RHb), but no signiﬁcant
difference in oxygen saturation (StO2) (ratio of OHb to
THb). Therefore, increasing PAX6 level in U251HF cells
does not change cellular metabolic activity, but does sup-
press tumor angiogenesis.
PAX6 suppresses VEGFA expression in vivo
We compared the VEGFA gene expression in the glioma
cells in s.c. xenografts shown in Fig. 1, based on data from
real-time AqRT-PCR using human-speciﬁc gene primers
unable to amplify the murine homologues. As shown in
Fig. 1e, we found a signiﬁcantly lower level of VEGFA
expression in the s.c. xenografts of PAX6_2.2 compared to
those of U251HF; thus, PAX6-suppression of VEGFA
takes place in vivo as well as in vitro.
We then quantiﬁed the VEGFA expression in U251HF
and PAX6_2.2 s.c. xenografts in a different experiment in
which we remove the tumor at different times after
implantation. As respectively shown in Fig. 2a and b,
normalized VEGFA expression was found always higher,
and PAX6 always lower, in U251HF xenografts compared
to PAX6-2.2 xenografts that were grown for the same
period of time in vivo. However, PAX6 in the PAX6-2.2
xenografts showed a 20% decrease in 15-day tumors
compared to 11-day tumors (Fig. 2b), suggesting a nega-
tive selection pressure on the cells overexpressing PAX6
in vivo. Consistent with this ﬁnding, immunostaining of
PAX6 in the 24-day PAX6_2.2 tumors showed loss of
PAX6 signal in some tumor cells (Fig. 2d). Co-staining for
PAX6 and VEGFA in PAX6_2.2 tumors showed distinct
areas of cells with expression of either PAX6 or VEGFA
but not both. This is consistent with the trends in Fig. 2a
and b, which show that the decrease in PAX6 correlates
Fig. 2 Decrease of PAX6 is related to increase of VEGFA expression
during tumor growth. a–b Comparison of PAX6 and VEGFA mRNA
levels in U251HF and PAX6-2.2 cells grown in vitro or in vivo under
nude mice skin at various time. The gene expression was quantiﬁed
by real-time qRT-PCR, normalized to GAPDH, and compared with
U251HF arbitrarily set to unity. c Comparison of tumor volumes that
were measured 6 days after s.c. implantation of U251HF and PAX6-
2.2. d Co-immunostaining PAX6_2.2 xenografts 24 days after
implantation showing single pictures of PAX6 staining and VEGFA
staining and merge picture of PAX6 and VEGFA, with cell nucleus
counterstained by DAPI
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Importantly, the transient changes in PAX6 and VEGFA
mRNA levels in the tumors are related to increase of the
tumor volumes (Fig. 2c). Overall, these results indicate that
PAX6-mediated suppression of VEGFA expression is
responsible for the suppression of tumorigenicity of glio-
mas, which is shown to be related with suppression of
angiogenesis.
PAX6 downregulation of VEGFA expression
at transcription level requiring its DNA-binding domain
We then examined in vitro cell cultures under normoxic
condition for changes on secretion of VEGFA in condi-
tioned medium by U251HF and multiple clones of its
stable transfectants of wild-type or mutant forms of PAX6.
As shown in Fig. 3a, it is the expression of wild-type
PAX6, not the mutant forms of PAX6, that changed the
VEGFA level secreted by the modiﬁed cells.
We further investigated PAX6 regulation of VEGFA
promoter activity. The transcriptional regulation of the
VEGFA promoter seems to play the pre-eminent role in the
control of VEGFA expression, and several response ele-
ments within the VEGFA promoter region have been
characterized in vitro. A key region of the VEGFA pro-
moter, located at approximately -930 from the transcrip-
tion initiation site, is a target for a number of transcription
factors, including HIF1A, TP53, VHL, and SP1. We thus
investigated VEGFA promoter activity by transfection of
luciferase constructs containing various regions of the
VEGFA promoter (2.6, 1.5, 0.35 and 0.2 kb as described
previously [17]) in U251HF and its PAX6-transfectants.
Since the suppressive effects of PAX6 on the VEGFA
promoter were observed in all promoter constructs in
PAX6_2.2 cells (data not shown), we focused on examin-
ing the 0.2 kb VEGFA promoter, which contains the -52/
?144 promoter sequence. This region does not contain any
of the binding sites for HIF1A, TP53, VHL, and SP1. As
shown in Fig. 3b, the -52/?144 VEGFA promoter activity
was lower in all three PAX6-transfectants compared to the
parental cell line U251HF; the average of activities relative
to U251HF among the three transfectants was 40%
(P\0.0001). Overall, the data showed that PAX6 sup-
pressed VEGFA expression in glioma cells under normoxic
in vitro and subcutaneous in vivo conditions.
PAX6-mediated regulation of VEGFA expression
is independent of HIF1A or VHL
Although VEGFA expression is regulated via complex
pathways, regulation of HIF1A synthesis and stability has
been considered to be the central mechanism underlying
regulation of VEGFA expression. The tumor suppressor
PTEN was reported to suppress VEGFA expression by
Fig. 3 PAX6 regulation of VEGFA expression. a Comparison of
secreted VEGFA quantiﬁed by VEGF-165 ELISA from condition
medium of cells expressing transfected cDNA constructs of wild-type
or two mutant forms of PAX6 (dmt and 344) to the parental glioma
cell U251HF, which was arbitrarily set to unity. Bonferroni adjusted
P-value with fold of increase (?) and decrease (-) were shown with
averages for the clones use for comparison. On top depicts the PAX6
mutants in functional domains, with PAI and RED and HD represent
three DNA-binding domain of PAX6, with two point mutations in the
paired domain R26G and I87R reported to cause loose of in vitro
DNA binding ability [7]. b Luciferase assays of VEGF promoter
activities in U251HF and three of U251HF PAX6 transfected clones,
with comparison of -52/?144 VEGF promoter activities between
parental and PAX6-transfected cells. Mean and SD were from 4 to 8
repeats of transfection and luciferase assay, which were carried out in
2–4 independent experiments
196 J Neurooncol (2010) 96:191–200
123blocking the PI3K/Akt signaling pathway with sub-
sequent reduction of HIF1A protein level under a
normoxic environment [18]. We thus examined the pos-
sible inﬂuence of PAX6 on regulation of VEGFA through
the PI3K/Akt signaling pathway. Western blots were used
to detect the activation of the PI3K/Akt signaling path-
way in response to adenoviral-mediated overexpression
of PAX6 in glioma cells. The result showed that PAX6
did not attenuate the phosphorylation of Akt and GSK3B
(Fig. 4a), nor the level of HIF1A (Fig. 4b), in contrast to
what was found with adenoviral-mediated overexpression
of PTEN in glioma cells.
Data from real-time AqRT-PCR quantiﬁcation of the
VHL gene expression revealed a high expression of VHL in
U251HF cells: more than 4-fold higher than the level of the
reference gene ENO1 (Fig. 4c, ﬁrst column). We further
examined VHL expression 48 h following infection of
U251HF cells with adenovirus of PAX6 (Ad-PAX6), with
Ad-PTEN, or with both, in two independent experiments.
Compared to the mock infection, Ad-PAX6 transfection
produced a reduction in the VHL/ENO1 expression ratio of
25% when used alone (Fig. 4c, second column; P = 0.035)
and 27% when co-transfecting with Ad-PTEN (Fig. 4c,
fourth column; P = 0.026), whereas transfection with Ad-
PTEN alone produced a 36% increase in VHL/ENO1
(Fig. 4c, third column; P = 0.027). Since the VHL-
expression changes in U251HF cells did not support a
suppressive function on VEGFA expression following
overexpression of PAX6 alone or together with PTEN, it
implies that VHL is unlikely to contribute to PAX6 sup-
pression of VEGFA expression.
PAX6 suppression of VEGFA expression was enhanced
by blocking PI3K/Akt signaling pathway
Based on data shown above, PAX6 does not activate the
PI3K/Akt signaling pathway, which suggests that the
mechanism by which PAX6 suppresses VEGFA differs
from that by which PTEN suppresses VEGFA. In agree-
ment with this conclusion, we observed that co-transfection
of U251HF cells with Ad-PAX6 and Ad-PTEN enhanced
suppression of VEGFA at the levels of both mRNA
(Fig. 5a) and secreted VEGFA (Fig. 5b), while no change
was seen from transfection with Ad-GFP, excluding pos-
sible viral effect. Statistical analysis showed that PAX6 and
PTEN work on mRNA levels in an additive manner, i.e.
with no signiﬁcant synergism or antagonism (Table 1). The
signiﬁcant main effects coupled with the lack of signiﬁcant
interaction shows that co-transfection with PAX6 and
PTEN produces signiﬁcantly more suppression of VEGFA
expression than either mono-transfection.
Consistent with PTEN blockage of PI3K/Akt signaling
to mediate suppression of VEGFA expression, treatment of
cells with the PI3K inhibitor, LY294002, also gave rise to
reduction of VEGFA expression in a dose-dependent
manner. Co-treatment of Ad-PAX6 and LY294002 further
increased the suppression of VEGFA. As shown in Fig. 5a,
treatment of U251HF cells with LY294002 alone for 48 h
decreased VEGFA expression, to 72% (normalized to
GAPDH) and 64% (normalized to ENO1) with a 2 lM
dose, and to 65% (normalized to GAPDH) and 49% (nor-
malized to ENO1) with a 10 lM dose. In the same culture
condition, infection of Ad-PAX6 alone at a lower dose (10
Fig. 4 PAX6 does not alter PI3K/Akt signaling and HIF1A level in
glioma cells under normoxic condition. By Western blot assay,
phosphorylation status of Akt and the downstream target GSK-3b (a)
and HIF1A level (b) were shown unchanged in U251HF cells 48 h
after treatment of cells with of Ad-PAX6. Analysis of cells with Ad-
PTEN infection was positive control for antibodies, and detections of
Actin as control equal protein loading while PAX6 and PTEN for
positive infections. c AqRT-PCR revealed the level of VHL expres-
sion relative to ENO1 in U251HF cells with or without adenoviral
infections. The mean and SD are based on data of two independent
experiments, with viral dose of 10 viral partial per cell, cultured for
48 h under serum-free condition after 1 h of infection. P-values are
shown for comparisons to mock infection, and are computed using
Dunnett’s ANOVA post-hoc procedure
J Neurooncol (2010) 96:191–200 197
123viral particles per cell) decreased the expression of VEGFA
down to 74% (normalized to GAPDH) and 81% (normal-
ized to ENO1). However, combined treatment with Ad-
PAX6 and LY294002 enhanced the overall suppression of
VEGFA, yielding expression levels of 55% (normalized to
GAPDH) or 53% (normalized to ENO1) with 2 lM
LY294002, and expression levels of 44% (normalized to
GAPDH) or 37% (normalized to ENO1) with 10 lM
LY294002. Statistical analysis showed that PAX6 and
LY294002 work in an additive manner, i.e. with no sig-
niﬁcant synergism or antagonism (Table 1).
Similar effects on the enhanced suppression of VEGFA
by co-overexpression of PAX6 and PTEN were observed
in another glioma cell line, U87. Interestingly, such
enhancement can be achieved only when the cells were
co-infected by Ad-PAX6 and Ad-PTEN, regardless of
whether conditions were normoxic or hypoxic (Fig. 6).
Changesincellviabilityaftervialinfectionweredetermined
to be minimal based on a Trypan Blue exclusion assay.
Infection of another glioma cell line LN229 with Ad-
PAX6 alone or together with Ad-PTEN at a lower dose (10
viral particles per cell) decreased the expression of VEGFA
down to 70% (normalized to GAPDH or ENO1) (Fig. 6b).
But since Ad-GFP also caused a similar level of reduction
when normalized to GAPDH, it brings the attention to viral
effect in LN229. Trypan Blue exclusion assay showed that
LN229 is sensitive to adenoviral infection as well as
LY294002 treatment, which apparently cause reductions of
ENO1 expression and increase of VEGFA/ENO1 values in
Ad-GFP and LY294002 treatments. In contrast to Ad-
PAX6, Ad-PTEN slightly increased VEGFA expression in
LN229 by about 1.5 fold (Fig. 6b). Glioma cell line LN229
is one of the few glioma cell lines that has a wild-type form
of the PTEN gene. We compared the basal VEGFA
expression in LN229 with other glioma cell lines with
mutant PTEN. As shown in Fig. 6c, basal VEGFA
expression in LN229 is low; 4 or 9% of U251HF normal-
ized to GAPDH or ENO1, respectively, and 2 or 6% of U87
normalized to GAPDH or ENO1, respectively. Thus
VEGFA expression in LN229 apparently is under partial
suppression, and can be further suppressed by PAX6 such
that expression is nearly blocked, but cannot be further
suppressed by increasing PTEN-blockage of PI3K/Akt
signaling.
Discussion
Our data show, for the ﬁrst time, that PAX6 acts as a tumor
suppressor in glioma cells by suppressing angiogenesis,
and that VEGFA is a target of PAX6-mediated pathways in
Fig. 5 PAX6 suppression of VEGFA expression was enhanced by co-
expression of PTEN or blocking Akt-signaling pathway in U251HF
cells under normoxic condition. Comparison of VEGFA expression in
U251HF cells after treatment Ad-PAX6 and/or Ad-PTEN, and/or
PI3K inhibitor LY294002 at mRNA level (a) and at secreted protein
level (b). Bonferroni adjusted P value were shown
Table 1 Statistical analysis of VEGFA expressions normalized to
either GAPDH or ENO1 in U251HF cells response to Ad-PAX6, Ad-
PTEN, and LY294002 by post-hoc comparisons and contrasts of the
treatments
Effect on VEGFA expressions F-statistics
a DF
b P values
c
PAX6 main effect ± PTEN 30.03 (1,24) \0.0001
11.49 \0.0001
PTEN main effect ± PAX6 56.81 (1,24) \0.0001
13.93 \0.0001
PAX6-by-PTEN interaction 0.67 (1,24) 0.42
1.99 0.17
PAX6 main effect ± LY294002 34.12 (1,24) \0.0001
34.09 \0.0001
LY294002 main effect ± PAX6 136.10 (2,24) \0.0001
36.60 \0.0001
PAX6-by-LY294002 interaction 0.34 (2,24) 0.72
0.42 0.66
a Contrast F-statistics for indicated effect. Top: VEGFA/ENO1;
bottom: VEGFA/GAPDH
b Contrast degrees of freedom (DF) for indicated effect, expressed as
(effect DF, error DF)
c Contrast P values for indicated effect. Top: VEGFA/ENO1; bottom:
VEGFA/GAPDH
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123a normoxic condition. We found that PAX6 suppression of
VEGFA is under a mechanism different from the canonical
mechanism involving HIF1A and VHL. Consequently, an
additive suppressive effect on VEGFA expression was seen
by introduction of both PAX6 and PTEN or PAX6 and
PI3K inhibitor. Yet our data from this study did not identify
a mediator of the PAX6 reduction of VEGFA promoter
activity and consequent mRNA expression. Through
transfection of different forms of PAX6 mutants, we
determined that PAX6 needs its DNA-binding domain to
suppress VEGFA expression, but this study did not solve
the question of whether PAX6 functions directly to bind
the VEGFA promoter or indirectly via another transcrip-
tion factor. Data from this study reveal that PAX6 medi-
ated a novel mechanism for regulating VEGFA expression
that is independent of the PI3K/Akt-HIF1A-VHL pathway.
In this study, we used the s.c. xenograft glioma model to
study the direct effect of PAX6 on angiogenesis. In this
model, we can avoid complications delineating the mech-
anisms affecting angiogenesis in the brain, where angio-
genesis can also be affected by microglia/microphage
inﬁltration [22, 24]. Since PAX6 was found to suppress
expression of the gene encoding chemokine (C–C motif)
ligand 2 (CCL2) in glioma cell lines [25], using a s.c.
xenograft model allowed us to exclude the microglia effect
on angiogenesis in an intracranial xenograft model. With
regards to the potential regulation of inﬂammation-induced
angiogenesis by PAX6 expression in glioma cells, the
intracranial xenograft model will be used. Identiﬁcation of
PAX6 regulation of VEGFA expression and the underlying
mechanisms will provides new clues to dissect the com-
plexity of mechanisms underlying glioma angiogenesis.
Acknowledgments This work was supported in part by the
Arkansas Cancer Research Center at the University of Arkansas for
medical sciences, and University of California, Irvine, Committee on
Research Award.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Simpson TI, Price DJ (2002) Pax6; a pleiotropic player in
development. Bioessays 24:1041–1051
2. Mansouri A, Hallonet M, Gruss P (1996) Pax genes and their
roles in cell differentiation and development. Curr Opin Cell Biol
8:851–857
3. Sander M, Neubuser A, Kalamaras J, Ee HC, Martin GR, German
MS (1997) Genetic analysis reveals that PAX6 is required for
normal transcription of pancreatic hormone genes and islet
development. Genes Dev 11:1662–1673
4. Osumi N, Shinohara H, Numayama-Tsuruta K, Maekawa M
(2008) Concise review: Pax6 transcription factor contributes to
both embryonic and adult neurogenesis as a multifunctional
regulator. Stem Cells 26:1663–1672
Fig. 6 Regulation of VEGFA expression in U87 and LN229 by
PAX6 or blocking of PI3K/Akt signaling. a VEGF-165 ELISA data
on the secreted VEGFA protein in condition medium of cells infected
with Ad-PAX6 alone or together with Ad-PTEN simultaneously or
separate with 1 day apart, under normoxic and hypoxic conditions.
Mean and SD were from 1 to 2 independent experiments, with
P-values shown for comparison to mock infection. b Comparison of
VEGFA expression in LN229 cells after treatment Ad-PAX6 and/or
Ad-PTEN, and/or PI3K inhibitor LY294002 at mRNA level.
c comparison of PAX6 and VEGFA expressions in U251HF, U87
and LN229. X marks zero expression value for PAX6 in LN229;
PTEN status (mt, mutant or wt, wild type) in these cell lines is based
on information in [23]
J Neurooncol (2010) 96:191–200 199
1235. Zhou YH, Tan F, Hess KR, Yung WK (2003) The expression of
PAX6, PTEN, vascular endothelial growth factor, and epidermal
growth factor receptor in gliomas: relationship to tumor grade
and survival. Clin Cancer Res 9:3369–3375
6. Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K,
Hess KR, Gumin J, Lang F, Yung WK (2005) PAX6 suppresses
growth of human glioblastoma cells. J Neurooncol 71:223–229
7. Mayes DA, Hu Y, Teng Y, Siegel E, Wu X, Panda K, Tan F,
Yung WK, Zhou YH (2006) PAX6 suppresses the invasiveness of
glioblastoma cells and the expression of the matrix metallopro-
teinase-2 gene. Cancer Res 66:9809–9817
8. Chang JY, Hu Y, Siegel E, Stanley L, Zhou YH (2007) PAX6
increases glioma cell susceptibility to detachment and oxidative
stress. J Neurooncol 84:9–19
9. CBTRUS, Central Brain Tumor Registry of the United States
(2005) Statistical report: primary brain tumors in the United
States, 1997-2002. CBTRUS, Chicago
10. Norden AD, Drappatz J, Wen PY (2008) Antiangiogenic therapy
in malignant gliomas. Curr Opin Oncol 20:652–661
11. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas
J, Schwiertz A, Jurgensen JS, Gruber G, Maxwell PH, Loning
SA, Frei U, Maher ER, Grone HJ, Eckardt KU (2001) Consti-
tutive activation of hypoxia-inducible genes related to overex-
pression of hypoxia-inducible factor-1alpha in clear cell renal
carcinomas. Cancer Res 61:5215–5222
12. Damert A, Machein M, Breier G, Fujita MQ, Hanahan D, Risau
W, Plate KH (1997) Up-regulation of vascular endothelial growth
factor expression in a rat glioma is conferred by two distinct
hypoxia-driven mechanisms. Cancer Res 57:3860–3864
13. Guan M, Jin J, Su B, Liu WW, Lu Y (2002) Tissue factor
expression and angiogenesis in human glioma. Clin Biochem
35:321–325
14. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y
(1996) Expression of tissue factor correlates with grade of
malignancy in human glioma. Cancer 77:1877–1883
15. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J (2003)
Tissue factor expression correlates with tumor angiogenesis and
invasiveness in human hepatocellular carcinoma. Clin Cancer
Res 9:5339–5345
16. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T (2000) Tissue
factor, osteopontin, alphavbeta3 integrin expression in micro-
vasculature of gliomas associated with vascular endothelial
growth factor expression. Br J Cancer 82:1967–1973
17. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Suk-
hatme VP (1997) The von Hippel-Lindau tumor suppressor gene
product interacts with Sp1 to repress vascular endothelial growth
factor promoter activity. Mol Cell Biol 17:5629–5639
18. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M,
Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK (2003) Mecha-
nisms underlying PTEN regulation of vascular endothelial growth
factor and angiogenesis. Ann Neurol 53:109–117
19. Zhou YH, Hess RK, Liu L, Linskey ME, Yung WKA (2005)
Modeling prognosis for patients with malignant astrocytic glio-
mas: quantifying the expression of multiple genetic markers and
clinical variables. Neuro Oncol 7:485–494
20. Wesseling P, van der Laak JA, de Leeuw H, Ruiter DJ, Burger PC
(1994) Quantitative immunohistological analysis of the micro-
vasculature in untreated human glioblastoma multiforme.
Computer-assisted image analysis of whole-tumor sections.
J Neurosurg 81:902–909
21. Cuccia DJ, Bevilacqua F, Durkin AJ, Tromberg BJ (2005)
Modulated imaging: quantitative analysis and tomography of
turbid media in the spatial-frequency domain. Opt Lett 30:1354–
1356
22. Platten M, Kretz A, Naumann U, Aulwurm S, Egashira K, Is-
enmann S, Weller M (2003) Monocyte chemoattractant protein-1
increases microglial inﬁltration and aggressiveness of gliomas.
Ann Neurol 54:388–392
23. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC,
Van Meir EG (1999) Frequent co-alterations of TP53, p16/
CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol 9:469–479
24. Goede V, Brogelli L, Ziche M, Augustin HG (1999) Induction of
inﬂammatory angiogenesis by monocyte chemoattractant protein-
1. Int J Cancer 82:765–770
25. Zhou YH, Glass T, Yung WKA (2001) PAX6 down regulate the
expression of PDGFRA and MCP-1 genes in glioblastoma cells.
Neuro Oncol 3:312
200 J Neurooncol (2010) 96:191–200
123